These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 4094068)

  • 41. Clinical experience with aztreonam in four Mediterranean countries.
    Daikos GK
    Rev Infect Dis; 1985; 7 Suppl 4():S831-5. PubMed ID: 2934787
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Brogden RN; Heel RC
    Drugs; 1986 Feb; 31(2):96-130. PubMed ID: 3512234
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aztreonam activity, pharmacology, and clinical uses.
    Neu HC
    Am J Med; 1990 Mar; 88(3C):2S-6S; discussion 38S-42S. PubMed ID: 2180293
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinical evaluation of aztreonam for infections accompanying febrile neutropenic children with hematologic disorders and solid tumors. A cooperative study].
    Hirotsu T; Akatsuka J; Hoshi Y; Uchiyama H; Fujisawa K; Kobayashi N; Ishidoya N; Ohira M; Takayama J; Ishida Y
    Jpn J Antibiot; 1990 Dec; 43(12):2069-77. PubMed ID: 2086821
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Pharmacokinetics and clinical evaluations on aztreonam in perinatal infections in obstetrics and gynecology. A study of aztreonam in the perinatal co-research group].
    Matsuda S; Oh K; Hirayama H; Shimizu T; Sengoku K; Haga H; Inoue R; Yamazaki T; Mizoguchi H; Tori-i Y
    Jpn J Antibiot; 1990 Apr; 43(4):736-53. PubMed ID: 2199691
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of low-dose aztreonam in the treatment of moderate to severe infections due to gram-negative bacilli.
    Clergeot A; Steru D; Rosset MA; Carbon C
    Rev Infect Dis; 1991; 13 Suppl 7():S648-51. PubMed ID: 2068476
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aztreonam in the treatment of gram-negative meningitis and other gram-negative infections.
    Feris J; Moledina N; Rodriguez WJ; Khan WN; Puig J; Wiedermann BL; Ahmad S
    Chemotherapy; 1989; 35 Suppl 1():31-8. PubMed ID: 2731448
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Preclinical and clinical studies on aztreonam in the field of obstetrics and gynecology].
    Obata I; Hayashi F; Imagawa N; Ochiai K; Koike K; Morimoto O; Hachiya S
    Jpn J Antibiot; 1985 Dec; 38(12):3542-60. PubMed ID: 3834138
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aztreonam therapy for serious gram-negative infections in children.
    Stutman HR; Chartrand SA; Tolentino T; Friedhoff L; Marks MI
    Am J Dis Child; 1986 Nov; 140(11):1147-51. PubMed ID: 3766490
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aztreonam in the treatment of serious gram-negative infections in the elderly.
    Deger F; Douchamps J; Freschi E; Thys JP; Nève P; Herchuelz A
    Int J Clin Pharmacol Ther Toxicol; 1988 Jan; 26(1):22-6. PubMed ID: 3403089
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Clinical evaluation of aztreonam in neonatal infections].
    Okura K; Matsuda T; Nigami H; Yamakawa M; Kuroki S; Haruta T; Kobayashi Y
    Jpn J Antibiot; 1990 Mar; 43(3):493-502. PubMed ID: 2374299
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Carbapenems and monobactams: imipenem, meropenem, and aztreonam.
    Hellinger WC; Brewer NS
    Mayo Clin Proc; 1999 Apr; 74(4):420-34. PubMed ID: 10221472
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aztreonam therapy for serious gram-negative bacillary infections.
    Cone LA; Woodard DR
    Rev Infect Dis; 1985; 7 Suppl 4():S794-802. PubMed ID: 3909339
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A multicenter comparative trial of aztreonam in the treatment of gram-negative infections in compromised intensive-care patients.
    Rabinad E; Bosch-Perez A
    Chemotherapy; 1989; 35 Suppl 1():1-7. PubMed ID: 2659288
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [In vitro activity and clinical evaluation of aztreonam in the field of obstetrics and gynecology].
    Ninomiya K; Ohbayashi F; Hasegawa Y
    Jpn J Antibiot; 1985 Dec; 38(12):3629-33. PubMed ID: 3834148
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Successful response of severe neonatal gram-negative infection to treatment with aztreonam.
    Constantopoulos A; Thomaidou L; Loupa H; Papoulias G
    Chemotherapy; 1989; 35 Suppl 1():101-5. PubMed ID: 2731446
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Pharmacokinetics and clinical studies on aztreonam in neonates].
    Arai S; Sono R; Shibata T; Sakurai M; Ihara T; Kamiya H; Inamochi H; Nomura T; Taki N; Suzuki M
    Jpn J Antibiot; 1990 Mar; 43(3):479-86. PubMed ID: 2374297
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Aztreonam treatment of severe infections caused by gram-negative aerobic bacilli].
    Peter JD; Jehl F; Froehly S; Dupeyron JP; Monteil H; Rosset MA
    Pathol Biol (Paris); 1988 May; 36(5):525-30. PubMed ID: 3043352
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Evaluation of the clinical effectiveness of aztreonam in gram-negative infections of the biliary tract].
    Pedretti G; Magnani G
    G Ital Chemioter; 1988; 35(1-3):45-8. PubMed ID: 3256512
    [No Abstract]   [Full Text] [Related]  

  • 60. Aztreonam in the treatment of urinary tract infections: a multicenter trial.
    Martelli A; Cortecchia V; Ventriglia L
    Chemotherapy; 1989; 35 Suppl 1():8-14. PubMed ID: 2659294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.